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AbstrACt
Introduction Empirical, observational data relating 
to the diagnosis, management and outcome of three 
common worldwide cancers requiring surgery is lacking. 
However, it has been demonstrated that patients in low/
middle-income countries undergoing surgery for cancer 
are at increased risk of death and major complications 
postoperatively. This study aims to determine quality and 
outcomes in breast, gastric and colorectal cancer surgery 
across worldwide hospital settings.
Methods and analysis This multicentre, international 
prospective cohort study will be undertaken by any 
hospital providing emergency or elective surgical services 
for breast, gastric or colorectal cancer. Centres will collect 
observational data on consecutive patients undergoing 
primary emergency or elective surgery for breast, 
gastric or colorectal cancer during a 6-month period. 
The primary outcome is the incidence of mortality and 
major complication rate at 30 days after cancer surgery. 
Infrastructure and care processes in the treatment of these 
cancers worldwide will also be characterised.
Ethics and dissemination This project will not affect 
clinical practice and has been classified as clinical 
audit following research ethics review. The protocol will 
be disseminated through the international GlobalSurg 
network.
trial registration number NCT03471494; Pre-results.
IntroduCtIon
Of the 15.2 million individuals diagnosed 
with cancer in 2015, 80% required surgery.1 
In tumours amenable to surgical resection, 
surgery often offers the best chance of cure, 
particularly in early stage disease. It has been 
estimated that 45 million surgical procedures 
are needed each year worldwide, yet fewer 
than 25% of patients with cancer have access 
to safe, affordable and timely surgery. While 
death rates from cancer are decreasing in 
high-income countries, the opposite has 
been demonstrated in low/middle-income 
countries (LMICs).2 Up to 1.5% of the gross 
domestic product is lost because of cancer in 
some LMIC regions.3 
Our recent LMIC-led three-stage research 
prioritisation exercise identified cancer 
surgery as a major research priority. Breast 
cancer, gastric cancer and colorectal cancer 
represent a significant burden of disease 
across income settings.1 2 Yet, most studies 
that examine the global distribution and 
outcomes of solid cancers use simulated 
methods due to the absence of robust data, 
including country-specific information on 
cancer epidemiology, stage distribution and 
treatment approaches.1
Our previous prospective, observational 
cohort studies GlobalSurg 1 and 24 5 have 
demonstrated that patients in LMICs have 
an increased risk of death and complications 
following gastrointestinal cancer surgery. 
These differences persisted in multivariable 
strengths and limitations of this study
 ► This will be the first international, multicentre, pro-
spective study to assess quality and outcomes in 
patients undergoing surgery for three of the most 
common global cancers.
 ► The collaborative methodology adopted by our 
group, as described elsewhere, has previously deliv-
ered two large high-quality studies, while avoiding 
overburdening low-resource centres that may other-
wise be unable to participate in such projects.
 ► Definitions of quality in surgical cancer care are dis-
puted and little evidence exists of their validity or ap-
propriateness in low- and middle-income countries; 
high-quality data will help identify specific measures 
for cancer care in resource-limited settings.
 ► Only those patients undergoing primary surgery for 
breast, gastric or colorectal cancers will be includ-
ed, and therefore outcomes in patients receiving 
only conservative or oncological therapy will not be 
included.
 ► As strict primary data monitoring is not possible 
within the limitations of the study, we will use a 
previously developed mixed-methods validation 
process.
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models accounting for confounders in mortality (OR 
3.18, 95% CI 2.12 to 4.76), major complication (OR 2.14, 
95% CI 1.19 to 3.84) and SSI (OR 1.32, 95% CI 1.04 to 
1.68) at 30 days after surgery. Postoperative complica-
tions can have a more severe consequences in LMICs, 
including death, long-term disability and catastrophic 
healthcare expenditure.6
The measures used to determine the quality of surgical 
cancer care are controversial and subject to ongoing 
debate. Guidelines produced by bodies such as the 
National Institute for Health and Care Excellence (UK) 
and American College of Surgeons in high-income coun-
tries provide some consensus.7 8 However, there is little 
evidence on the appropriateness of such guidelines in 
LMICs or what specific measures may indicate quality in 
cancer surgery in resource-poor settings.
The aim of the GlobalSurg 3 study is to determine vari-
ation in the quality of cancer surgery worldwide, focusing 
on patient outcomes, infrastructure and care processes. 
This study is driven from within our well-established 
global network and will be performed in upwards of 85 
countries.
Primary aims
The primary aim is to audit 30-day mortality and compli-
cation rates after cancer surgery across low-human, 
middle-human and high-human development index 
(HDI) countries.
secondary aims
The secondary aim is to measure the quality of surgical 
cancer care and is designed to be relevant in low-income, 
middle-income and high-income settings. Conditional 
data points will be dependent on the specific resources 
available in a hospital and will include infrastructure, care 
process measures and outcomes.
MEthods And AnAlysIs
This is a multicentre, international, prospective, observa-
tional cohort study of all consecutive patients undergoing 
surgery for breast, gastric or colorectal cancer over a 
28-day period. Individual collaborators are free to choose 
any 28-day period within the 6-month study period to 
collect data. This ‘snapshot’ study design is a validated 
model that has been delivered successfully in previous 
studies.4 5 9
the research collaborative
GlobalSurg (http:// globalsurg. org/) is a collaboration 
between practising surgeons from around the world, 
performing research in surgery to foster local, national 
and international research networks. The collaborative 
model used has previously been described elsewhere10 
and has already facilitated two multicentre, international, 
prospective cohort studies including a total of 26 228 
patients undergoing emergency and elective abdom-
inal surgery.4 5 The NIHR Unit on Global Surgery was 
established in 2017 and is a consortium between the 
Universities of Birmingham, Edinburgh and Warwick, 
together with international partners. The units objec-
tive is to advance the education of medical students and 
doctors in surgical science, clinical research and audit 
methods by promoting participation in collaborative clin-
ical research and audit studies.
study setting
Any surgical unit providing emergency or elective surgery 
for breast, gastric or colorectal cancer worldwide is 
eligible to participate. An eligible hospital is not required 
to perform surgery for all three conditions; however, 
consecutive patients with breast, gastric or colorectal 
cancer managed surgically in an individual centre must 
be collected during the specified study period.
Included centres must capture all consecutive patients 
and ensure data collection is >90% complete. Centres 
with >10% missing data, when including all data points, 
will be excluded from the final analysis and removed from 
the authorship. There is no minimum number of patients 
per centre, as long as all eligible patients treated during 
the study period are included. Multiple teams covering 
different non-overlapping time periods at each hospital 
are encouraged.
Patient inclusion and exclusion criteria
Adult patients aged 18 years or over undergoing emer-
gency or elective surgery for breast, gastric or colorectal 
cancer are eligible to enter. Any operative approach or 
treatment intent can be used. Patients whose primary 
pathology is not suspected to be breast, gastric or 
colorectal cancer; have a recurrence of their cancer; 
or are undergoing a procedure that does not require 
a skin incision should be excluded (box 1). Each indi-
vidual patient should only be included once into the 
study.
box 1 Patient inclusion and exclusion criteria
Inclusion criteria
 ►  Adult patients aged 18 years or over.
 ► Consecutive patients undergoing therapeutic surgery (curative or 
palliative) for breast, gastric and colorectal cancer.
 ► Patients with suspected benign pathology preoperatively whom 
were subsequently found to have a diagnosis of cancer following 
their surgery.
 ► Undergoing emergency or elective procedure requiring a skin inci-
sion performed under general or neuraxial (eg, regional, epidural or 
spinal) anaesthesia.
 ► Includes open, laparoscopic, laparoscopic converted and robotic 
cases.
Exclusion criteria
 ► Operations with a sole diagnostic or staging intent.
 ► Procedures which do not require a skin incision.
 ► Patients with recurrence of breast, gastric or colorectal cancer.
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outcome measures
The primary outcome measure is the rate of mortality 
and major complication within 30 days of surgery. Major 
complications will be defined as occurrence of a Clavien-
Dindo11 grade III or IV (box 2) complication within 
30 days of index operation, where day of operation is day 
0.
The secondary outcomes that will be derived from this 
study include incidence of surgical site infection and 
predefined cancer-specific quality measures for infra-
structure and outcomes in cancer care (box 3–5).
data points
Data points relating to patient characteristics, cancer 
staging, neoadjuvant therapy, operative treatment and 
postoperative period will be collected (online supple-
mentary files 1–4). In order to maximise data completion, 
a minimal dataset has been designed including factors 
only relevant to quality and outcome measures in surgery 
for cancer. Review by international collaborators within 
the GlobalSurg Collaborative has also ensured the dataset 
is relevant to cancer surgery in a worldwide setting. 
Investigators will enter data via the secure internet-based 
Research Electronic Data Capture (REDCap) system.12 
Anonymous patient data will be held on the system hosted 
by the University of Edinburgh, Scotland, UK.
Investigators
The study will be undertaken by investigators around 
the world who will be responsible for disseminating the 
protocol at their individual site, ensuring appropriate 
study approvals are in place, identifying and including 
all eligible patients during each 4-week data collection 
period and responsible for accurate uploading of data to 
an online REDCap database.
box 2 Clavien-dindo classification of major postoperative 
complications11
Clavien-dindo grade III
 ► Unplanned surgical, endoscopic or radiological intervention.
 – IIIa: intervention not under general anaesthesia.
 – IIIb: intervention under general anaesthesia.
Clavien-dindo grade IV
 ► Life-threatening complication requiring unplanned critical care 
management.
 – IVa: single organ dysfunction (including dialysis).
 – IVb: multiorgan dysfunction.
box 3 breast cancer quality measures
Infrastructure and care processes
Availability and performance of:
 ► Preoperative fine needle aspiration/core biopsy to diagnose breast 
cancer.
 ► Breast/axillary MRI for staging.
 ► Breast conservation surgery for American Joint Committee on 
Cancer (AJCC) stage 0/I/II breast cancer.
 ► Axillary/breast radiotherapy and axillary lymph node clearance (at 
least 10 lymph nodes for analysis).
 ► Sentinel lymph node biopsy for early invasive breast cancer.
 ► Progesterone receptor, oestrogen receptor, human epidermal growth 
factor receptor 2 receptor and Ki67 status for invasive cancers.
 ► Treatment with adjuvant treatment where appropriate within 31 days 
of completion of surgery.
 ► Plan for radiotherapy for all with breast conserving surgery with 
clear margins (including ductal carcinoma in-situ [DCIS]).
 ► Treatment decisions made within multidisciplinary team meeting/
tumour board.
outcomes
 ► 30-day complication rate of surgical site infection, abscess forma-
tion, seroma, unplanned reoperation, unplanned readmission and 
requirement for unplanned critical care.
 ► Margin involvement (or ability to measure this locally) with ‘tumour 
on inked margin’ or a margin <2 mm in DCIS considered positive.
box 4 Gastric cancer quality measures
Infrastructure and care processes
Availability/performance of:
 ► Endoscopy and biopsy to reach a diagnosis of cancer.
 ► CT chest, abdomen and pelvis scan performed for preoperative 
staging.
 ► Preoperative or postoperative chemotherapy for gastric cancer.
 ► Treatment decisions made within multidisciplinary team meeting/
tumour board.
outcomes
 ► 30-day complication rate of surgical site infection, anastomotic leak, 
unplanned reoperation and requirement for unplanned critical care.
 ► At least 15 regional lymph nodes removed and pathologically exam-
ined for resected gastric cancer (or ability to measure this locally).
box 5 Colorectal cancer quality measures
Infrastructure and care processes
Availability/performance of:
 ► CT chest, abdomen and pelvis scan performed for preoperative 
staging.
 ► Preoperative MRI for rectal cancer.
 ► Planning and treatment with postoperative chemotherapy following 
resection for lymph node positive colon cancer.
 ► Treatment with preoperative chemotherapy/radiotherapy.
 ► Treatment decisions made within multidisciplinary team meeting/
tumour board.
 ► Stoma formation rate.
outcomes
 ► 30-day complication rate of surgical site infection, anastomotic leak, 
unplanned reoperation, unplanned readmission and requirement for 
unplanned critical care.
 ► Circumferential resection margin >1 mm (or ability to measure this 
locally).
 ► At least 12 regional lymph nodes removed and pathologically ex-
amined for resected colon cancer (or ability to measure this locally).
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A central study writing committee comprising of 
an internationally representative group of healthcare 
professionals will be responsible for data analysis, final 
manuscript drafting and submission. Individuals will be 
required to register their unit via the REDCap system and 
will be required to complete a training module prior to 
commencing data collection.
Countries with multiple sites will be assigned a country 
lead, who will be responsible for coordinating multiple 
teams across sites to ensure duplication of data does not 
occur. Where individual hospitals have a large number of 
local coordinators, a hospital lead will be appointed to aid 
coordination. A maximum of three local investigators can 
cover each 4-week data collection period, with the collec-
tion of multiple, non-overlapping collection periods by 
the same or different local investigators in a single centre 
possible. They will be responsible for gaining local audit, 
service evaluation or research ethics approval as appro-
priate to their institution.
Investigators will create clear mechanisms appropriate 
to their institution to identify and include all eligible 
patients, involving daily review of operating logbooks, 
multidisciplinary team meeting, admission and handover 
lists. This will include identifying clear pathways to accu-
rately collect baseline, cancer-specific and follow-up data 
within the normal limits of follow-up. Local arrangements 
may include daily review of the patient and notes focused 
on included data points, reviewing patient status in outpa-
tient clinics or via telephone interview at 30 days (if this is 
normal practice) and checking for readmission through 
handover lists. All investigators will be listed as collabora-
tors on resulting publications in accordance with previous 
consensus guidelines for collaborative group research.13
Quality of data
To ensure high data quality, a detailed protocol has 
been produced and published online. Translations into 
12 common languages has also been performed to ease 
investigator understanding, including Arabic, French, 
Hindi, Italian, Mandarin, Portuguese, Russian, Spanish 
and Swahili. Collaborators are encouraged to perform 
data input in real-time using the REDCap system, with 
an individual patient record requiring to be completed 
before submission is possible. Data quality rules will also 
ensure data quality, highlighting disparities in data fields 
to the local collaborator for review. Online training is 
available to collaborators prior to the commencement 
of data collection at their institution, detailing secure 
REDCap data entry, patient outcome assessment and 
disease-specific parameters.
data validation
Data validation will be performed in two parts across a 
group of representative centres similar to the structure 
successfully used in previous studies of this nature.5 Case 
ascertainment assessment will involve an independent 
investigator determining the number of eligible cases 
within a 4-week data collection centre and comparing this 
to the actual number of cases submitted. By comparing 
samples, a quantitative estimate of case ascertainment 
will be produced by the central data team. Second, vali-
dators will be asked to provide data for a subset of vari-
ables, two patient variables, two operation variables and 
two outcome measures in order to measure data accuracy.
statistical analysis and power calculation
Variation across different international health settings 
will be tested using the HDI,14 a composite statistic of life 
expectancy, education and income indices published by 
the United Nations. Bayesian multilevel logistic regression 
models will be constructed to account for case mix, with 
population stratification by hospital and country of resi-
dence incorporated as random effects with constrained 
gradients.
Further prespecified subgroup analyses will be made by 
geographical country grouping, cancer-type (including 
the separation of colonic and rectal tumours), emer-
gency versus elective surgery, performance status, pallia-
tive versus curative surgery, extent of staging and extent 
of pathological analyses. When assessing quality measures 
and processes similar patient groups will be compared, 
with potential confounding factors such as cancer-type, 
patient presentation, surgical intent and availability of 
adjuvant therapy accounted for within statistical models. 
Quality metrics as described earlier in the protocol will 
guide exploratory analysis into the global variation in 
surgical management and available resources. However, 
it is acknowledged that such guidelines, in the majority, 
are designed for high-income settings and therefore their 
attainment will not be considered mandatory or a poten-
tial definitive measure of care quality in global cancer 
surgery.
Data will not be analysed or reported at an individual 
surgeon or hospital level. Following analysis, results will 
be fed back to participants at the centre level, but no 
other centres will be identifiable.
Estimates of 30-day mortality for gastrointestinal cancer 
resection were determined using data from the Global-
Surg 1 and 2 studies.4 5 Stratification of results by HDI was 
performed, with prominent variation in 30-day mortality 
rate between high HDI and low/middle HDI groups seen 
after cancer surgery in both emergency surgery (11.6% 
[75/644] vs 27.3% [59/216]) and elective surgery (2.0% 
[30/1501] vs 5.5% [23/416]). An indicative sample size 
calculation using the smaller of these estimates suggests 
around 500 patients per group at 80% power (P1=0.020, 
P2=0.055, alpha=0.05) or 640 patients per group at 90% 
power would be required to conclude a difference in 
30-day mortality rate between HDI groups.
Patient and public involvement
Patient representatives for GlobalSurg, from both the UK 
and Rwanda, guided development of the research ques-
tion, outcomes measured and study design. Patients were 
not involved in the recruitment or conduct of the study. 
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We aim to publish the study results as open access, which 
will be readily available to patients and the public.
EthICs And dIssEMInAtIon
research ethics approval
The primary audit standards stems from the UK National 
Institute for Health Clinical Excellence7 and the Amer-
ican College of Surgeons Commission of Cancer Quality 
of Care8 guidelines for the diagnosis, investigation and 
management of breast, gastric and colorectal cancer 
(box 6). As this study will not change local clinical practice 
and is limited to using data obtained as part of usual care, 
it has been classified as an audit by the South Scotland 
Research Ethics Service in Edinburgh, Scotland (online 
supplementary file 5). Therefore, this may be consid-
ered a global audit or global service evaluation. Local 
investigators will be responsible for ensuring the study is 
registered appropriately and approval gained from the 
relevant local clinical audit departments, research and 
development department or institutional review boards. 
If such departments are unavailable, written permission 
should be supplied by the chief of surgery or responsible 
supervising consultant/attending physician.
Protocol dissemination
The protocol will be disseminated across the established 
GlobalSurg network, compromised of surgeons, medical 
students and clinical staff across the world. The network 
previously included over 1800 collaborators across 343 
centres representing 66 countries.5 Country leads are 
responsible for local coordination and dissemination 
within their country. In addition, the use of social media 
including Facebook, Twitter and YouTube has been 
shown to be an effective medium for dissemination of 
such collaborative projects15 and will also be employed.
dissemination of results
We aim to publish the study results as open access. Data from 
the study will be described to ensure individual countries, 
hospitals and surgeons are anonymous and then shall be 
deposited in an online data repository for others to analyse. 
On completion of the study, participating centres will be 
provided with their own benchmark performance and 
access to interactive web-based applications to use for quality 
improvement or subsequent reaudit. Based on the results of 
the GlobalSurg 3 study, feasibility studies investigating the 
collection of other outcome measures relating to cancer 
surgery and development of quality improvement and/or 
interventional clinical trials will be suggested for possible 
implementation in surgical cancer units for each included 
hospital in the study.
dIsCussIon
In this study protocol, we describe a multicentre, inter-
national, prospective cohort study investigating the 
quality and outcomes of surgery for three of the most 
common global cancers. Despite the likely increased risk 
of mortality and major morbidity for patients undergoing 
surgery for cancer in LMICs, high-quality, empirical data 
are currently unavailable. Furthermore, in countries with 
limited resources applicability of cancer surgery guide-
lines are yet to be tested.
By using a collaborative methodology and a short 4-week 
data collection period, the study will recruit sufficient 
patients to measure this, while avoiding burdening low-re-
source centres that may otherwise be unable to partici-
pate. Investigating the morbidity and mortality caused by 
cancer surgery globally, this study will provide a platform 
to build future quality improvement programmes and 
interventional trials as previously demonstrated by the 
GlobalSurg network.
This study will be delivered using an international 
multidisciplinary collaborative network of healthcare 
researchers, with the collaborative model having consis-
tently proven its ability to produce high-quality outcomes 
in international studies.4 5 A detailed study protocol in 
multiple languages, mandatory training, data quality 
control and validation period will ensure standardisation 
to deliver a reliable and accurate data set.
As the second most common cause of death in 2015, 
with 8.7 million deaths globally,2 cancer incidence is 
predicted to become an increasing burden worldwide1 2 
and place further pressure on already limited healthcare 
systems. Neoplasms already contribute to significant 
global morbidity and mortality, causing the highest loss of 
gross domestic product of any surgical disease.3 Surgery 
can provide cure for many cancers, particularly in coun-
tries where limited access to oncology treatment exists. 
However, the majority of the world’s population lack 
access to safe, affordable and timely cancer surgery.16
This study provides the first opportunity to collect and 
analyse prospective, observational data for three of the most 
common global cancers. Current literature is heavily reliant 
box 6 study audit standards
breast cancer
 ► American College of Surgeons Commission of Cancer Quality of 
Care for Breast Cancer.8
 ► National Institute for Health and Care Excellence (NICE): early and 
locally advanced breast cancer: diagnosis and treatment; Clinical 
Guideline CG80.17
 ► The Society of Surgical Oncology and the American Society for 
Radiation Oncology (SSO-ASTRO) consensus guidelines for early 
stage breast cancer.18
Gastric cancer
 ► American College of Surgeons Commission of Cancer Quality of 
Care for Gastric Cancer.8
 ► NICE: oesophago-gastric cancer: assessment and management in 
adults.19
Colorectal cancer
 ► American College of Surgeons Commission of Cancer Quality of 
Care for Colorectal Cancer.8
 ► NICE: colorectal cancer: diagnosis and management; Clinical 
Guideline CG131.20
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on simulated models based on limited data sources.2 3 16 
Our study will quantify any global inequalities in cancer 
surgery, highlight differences in patient presentation, treat-
ment interventions and surgical outcomes.
With feedback of outcomes and specific quality measures 
relating to each cancer, collaborators will have the oppor-
tunity to appraise their current practice against a global 
standard. Furthermore, surgeons and other interested 
parties will be able to use the findings from this study to help 
develop focused cancer surgery guidelines based on empir-
ical global data.
Finally, this study will continue to strengthen the 
international GlobalSurg network, further developing 
capacity for research in LMICs. Focused interventional 
trials derived from study findings will follow, aimed at 
improving global outcomes in cancer surgery.
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